Safety data from trials In a paper summarizing 6 randomized, double-blind, placebo-controlled human trials, AOD 9604 did not significantly affect IGF-1 levels, did not impair glucose tolerance, and no serious adverse events (SAEs) were attributed to AOD 9604
Prasopdee S, Tesana S, Cantacessi C, Laha T, Mulvenna J, Grams R, Loukas A, Sotillo J
Expected progression: Weeks one to two: Pain reduction, improved sleep (if night pain present) Weeks three to four: Increased range of motion, tolerance of rehab exercises improves Weeks five to eight: Significant functional improvement, return to activities Weeks eight to twelve: Continued tissue remodeling and strengthening For more on the general approach to peptides for joint pain , our dedicated guide covers the full landscape of options
Chorionic gonadotropin (HCG) injection [Label information]
Which pineal peptide should I start with
Most patients report feeling more energized within a day or two after treatment